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ABSTRACT
We previously described diaryl trifluorothiazoline compound 1a (hereafter 
referred to as fluorizoline) as a first-in-class small molecule that induces p53-
independent apoptosis in a wide range of tumor cell lines. Fluorizoline directly binds 
to prohibitin 1 and 2 (PHBs), two proteins involved in the regulation of several 
cellular processes, including apoptosis. Here we demonstrate that fluorizoline-induced 
apoptosis is mediated by PHBs, as cells depleted of these proteins are highly resistant 
to fluorizoline treatment. In addition, BAX and BAK are necessary for fluorizoline-
induced cytotoxic effects, thereby proving that apoptosis occurs through the intrinsic 
pathway. Expression analysis revealed that fluorizoline induced the upregulation of 
Noxa and Bim mRNA levels, which was not observed in PHB-depleted MEFs. Finally, 
Noxa-/-/Bim-/- MEFs and NOXA-downregulated HeLa cells were resistant to fluorizoline-
induced apoptosis. All together, these findings show that fluorizoline requires PHBs 
to execute the mitochondrial apoptotic pathway.
INTRODUCTION
Resistance to cell death is one of the hallmarks of 
cancer development, and it compromises the efficacy 
of conventional anti-cancer agents [1]. Hence, there is 
need for the development of novel apoptosis-inducing 
compounds as potential therapies for cancer. In a 
previous report we described the synthesis of a class 
of small molecules with an unprecedented fluorinated 
thiazoline scaffold as novel pro-apoptotic compounds [2]. 
Interestingly, the diaryl trifluorothiazoline compound 1a 
(Figure 1a), hereafter referred to as fluorizoline, triggered 
apoptosis through a p53-independent mechanism, which is 
highly relevant as half of all cancers acquire mutations in 
p53 during the malignant transformation [3]. In addition, 
we identified prohibitin 1 and 2 (PHBs) as proteins 
selectively binding to fluorizoline [2].
PHBs are evolutionary conserved, ubiquitously 
expressed proteins that are required for cellular 
proliferation, development, and the functional integrity 
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of mitochondria [4-6]. Consistently, depletion of PHBs 
leads to an impairment in embryonic development in 
Caenorhabditis elegans and mice [7-10]. PHBs are 
predominantly found in mitochondria, but they have also 
been identified in other cell compartments, including the 
plasma membrane and the nucleus [4, 11]. Within the 
inner mitochondrial membrane (IMM), PHB1 and PHB2 
interact with each other to form large heteromeric ring-
like complexes, which presumably serve as membrane 
scaffolds [6, 12]. Cells depleted of PHBs show fragmented 
mitochondria with an altered ultrastructure, as well as 
marked degradation of L-OPA1 [10, 13], a mitochondrial 
dynamin-like GTPase that mediates mitochondrial fusion 
and maintains cristae structure [14, 15]. In addition, PHBs 
have been linked to oxidative stress, as their absence 
induces the production of reactive oxygen species [16-19], 
and their overexpression protects against oxidative stress 
[18, 20, 21]. Loss of PHBs leads to impaired proliferation 
[10, 13, 22] and increased sensitivity to apoptotic stimuli 
[10, 11, 18, 23-25]. Thus, PHBs play a key role in the 
maintenance of the functional integrity of mitochondria, 
which ultimately allows proper cell and tissue homeostasis 
[4,6,26-28].
The role of PHBs in cancer remains controversial 
[11, 29]. An anti-tumorigenic role for PHBs was reported 
in various tumor cell types [30-33]. In contrast, PHBs have 
been linked to tumor growth, resistance to chemotherapy 
and metastasis [11, 29, 34]. The requirement of PHBs 
for cell proliferation strongly indicates a potential role 
in cancer progression [4, 11, 12, 22, 35]. Along this line, 
overexpression of PHB1 results in a higher resistance 
to apoptosis in different types of cancer cells, while 
downregulation of PHBs renders cancer cells more 
susceptible to pro-apoptotic insults [11, 21, 29, 36], 
suggesting a pro-tumorigenic role of PHBs.
In view of the pleiotropic functions of PHBs, these 
proteins emerge as highly interesting targets for the 
development of novel treatments for cancer [11, 29, 37]. 
In this regard, we propose that PHB-binding fluorizoline 
is a promising new agent due to its pro-apoptotic capacity. 
Here we further dissect the mechanism by which 
fluorizoline induces apoptosis and demonstrate that this 
compound requires PHBs to increase Noxa and Bim 
expression and to trigger the mitochondrial apoptotic 
pathway.
RESULTS
Fluorizoline requires the presence of prohibitins 
in order to induce apoptosis
We previously reported that fluorizoline (Figure 1a) 
binds specifically to PHB1 and PHB2 [2]. To examine 
whether the pro-apoptotic effects of this compound require 
PHBs, we sought to analyze the response of PHB-deficient 
cells to fluorizoline treatment. To this end, we used 
Phb2fl/fl MEFs, in which Cre-recombinase transduction 
induces loss of the Phb2 gene [10]. PHBs are 
interdependent at the protein level, thus loss of PHB2 
leads to the degradation of PHB1 [9, 10]. As a control, we 
used wild type (WT) MEFs, in which Cre-recombinase 
transduction does not modify PHB protein levels. 
Seventy-two hours after Cre-recombinase transduction, 
WT and Phb2fl/fl MEFs were treated with increasing doses 
of fluorizoline for 24 h, and cell viability was analyzed 
by flow cytometry. While WT MEFs were sensitive to 
fluorizoline treatment, loss of PHBs conferred strong 
resistance to fluorizoline-induced apoptosis in Cre-
transduced Phb2fl/fl MEFs (Phb2-/- MEFs) (Figure 1b). 
In contrast, both cell lines showed a similar response to 
Actinomycin D (ActD). Western blot analysis revealed 
that Cre-mediated depletion of Phb2 was accompanied 
by loss of PHB1 and L-OPA1 (Figure 1c), as previously 
described [10]. In addition, fluorizoline treatment led to 
cleavage of caspase 3 and poly ADP-ribose polymerase 
(PARP) in WT MEFs, thereby indicating induction of 
apoptosis. In contrast, the cleavage of these two proteins 
was clearly reduced in fluorizoline-treated Phb2-/- MEFs 
(Figure 1c). Contrary to fluorizoline, ActD triggered 
similar cleavage of caspase 3 and PARP in WT and Phb2-/- 
MEFs. Furthermore, disappearance of L-OPA1 forms was 
observed in fluorizoline- and ActD- treated WT MEFs.
Treatment with fluorizoline triggered apoptosis 
in WT and Phb2fl/fl MEFs in a similar manner in the 
absence of Cre-recombinase (Supplementary Figure 1a). 
Accordingly, fluorizoline and ActD induced a similar 
processing of caspase 3, PARP, and L-OPA1 in WT and 
Phb2fl/fl MEFs (Supplementary Figure 1b). These findings 
demonstrate that the resistance observed in Phb2-/- MEFs 
was not due to intrinsic insensitivity to apoptotic insults of 
the cell line but to the loss of PHBs.
In order to corroborate that lack of PHBs confers 
resistance to fluorizoline-induced apoptosis, Phb2 levels 
were downregulated by siRNA transfection in Phb2fl/fl 
MEFs. Reduction of Phb2 resulted in decreases of PHB1 
and L-OPA1 (Figure 1e). As expected, the pro-apoptotic 
effects of fluorizoline were blocked when PHBs were 
downregulated, as shown by flow cytometry and western 
blot analysis (Figure 1d-1e). These results were further 
confirmed by Phb2 siRNA transfection in WT MEFs 
(Supplementary Figure 1c-d). All together, these findings 
demonstrate that PHBs are necessary for fluorizoline-
induced apoptosis.
Furthermore, we sought to analyze whether 
modulation of PHB expression levels affects the sensitivity 
to fluorizoline. To this end, PHBs were overexpressed 
in Phb2fl/fl MEFs and the response to fluorizoline was 
examined. Interestingly, fluorizoline efficiently triggered 
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apoptosis in spite of PHB overexpression (Supplementary 
Figure 2a-b). Similar results were obtained by 
overexpressing PHBs in HeLa cells (Supplementary 
Figure 2c-d).
In addition, the pro-apoptotic effects of fluorizoline 
were analyzed in Phb2fl/- MEFs, which show lower levels 
of PHBs compared to Phb2fl/fl (Supplementary Figure 
3a). Cells were incubated with fluorizoline for 24 h and 
viability was analyzed by flow cytometry. Strikingly, 
Phb2fl/- and Phb2fl/fl clones displayed similar sensitivity to 
fluorizoline treatment (Supplementary Figure 3b). Taken 
together, these results show that the protein levels of PHBs 
do not strictly correlate with the sensitivity to fluorizoline. 
Resistance to fluorizoline can only be observed in the 
absence of PHBs.
Fluorizoline induces mitochondrial fragmentation 
and cristae disorganization
Upon apoptosis induction with various stimuli, the 
mitochondrial network undergoes extensive fragmentation, 
along with cristae remodeling [38-41]. Interestingly, this 
phenotype was also observed upon loss of PHBs, which 
was attributed to the accelerated processing of L-OPA1 
[10, 13]. We sought to analyze mitochondrial morphology 
and ultrastructure after fluorizoline treatment. HeLa 
cells incubated with fluorizoline presented fragmented 
mitochondria that clustered around the nucleus (Figure 
2a), as well as disarrangements of cristae, which appeared 
dilated and disorganized (Figure 2b). Higher magnification 
micrographs (60,000X) showed that incubation with 
fluorizoline induced partial or total loss of cristae, along 
with remodeling of the IMM into many separate vesicular 
Figure 1: The presence of PHBs is required for fluorizoline-induced apoptosis. a. Chemical structure of fluorizoline (diaryl 
trifluorothiazoline compound 1a). b., c. Cre recombinase was transduced in WT and Phb2fl/fl (Phb2-/-) MEFs for 72 h. Then cells were 
untreated (UT) or treated with either 0.15 µg/mL Actinomycin D (ActD) or increasing doses of fluorizoline (F) for 24 h. d., e. Phb2fl/fl MEFs 
were transfected with scramble (SC) or Phb2 (siPhb2) siRNA for 72 h. Afterwards, cells were treated with either 0.15 µg/mL Actinomycin 
D (ActD) or increasing doses of fluorizoline (F) for 24 h. b., d. Viability was measured by flow cytometry and it is expressed as the mean ± 
SEM (n ≥ 3) of the percentage of non-apoptotic cells (annexin V-negative). *p < 0.05, **p < 0.01, ***p < 0.001. c., e. Protein levels were 
analyzed by western blot. Tubulin and β-Actin were used as a loading control. These are representative images of at least three independent 
experiments. 
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and electron-lucent matrix compartments (Figure 2b). 
Therefore, these results show that fluorizoline treatment 
leads to mitochondrial fragmentation and cristae 
disorganization. These findings are consistent with the 
Figure 2: Treatment with fluorizoline induces changes in the mitochondrial morphology and ultrastructure. a. HeLa 
cells were treated with DMSO (vehicle) or 10 μM fluorizoline for 4 h. Mitochondria were stained with 100 nM MitoTracker® Red CMXRos 
and imaged using a confocal microscope. b. HeLa cells were incubated with DMSO (vehicle) or 2 μM fluorizoline for 24 h and changes 
in the mitochondrial morphology were visualized by transmission electron microscopy. Magnification at 6,000X (scale corresponding to 5 
μm), 20,000X (scale corresponding to 1 μm), and 60,000X (scale corresponding to 0.5 μm). Arrowheads indicate the mitochondria.
Figure 3: Fluorizoline induces ROS production independently of PHBs and apoptosis induction. a. Jurkat cells were 
untreated (UT), or treated with 10 μM fluorizoline (F) for 1 h or 200 μM tert-butyl hydroperoxide (TBHP) for 30 min. b. Jurkat cells were 
untreated (CT) or pre-incubated with 150 μM MnTBAP for 1 h and then treated with DMSO (D) or 10 μM fluorizoline (F) for 1 h. c. Jurkat 
cells were untreated (CT) or pre-incubated with 150 μM MnTBAP for 1 h and then treated with DMSO (D) or 10 μM fluorizoline (F) for 
24 h. Viability was measured by flow cytometry and it is expressed as the mean ± SEM (n = 3) of the percentage of non-apoptotic cells 
(annexin V-negative). d. Phb2fl/fl MEFs were transfected with scramble (SC) or Phb2 (siPhb2) siRNA for 72 h. Cells were then untreated or 
treated with 20 μM fluorizoline (F) for 1 hour. a., b., d. Superoxide anion and hydroxyl radical production was analyzed by flow cytometry 
using CellROX® Deep Red Reagent. Data show the mean values ± SEM relative to the mean of the control (a, n = 9; b, n = 3; d, n = 4). *p 
< 0.05, **p < 0.01, ***p < 0.001.
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capacity of fluorizoline to induce apoptosis and with PHBs 
being the target of this compound.
To analyze the role of OPA1 in fluorizoline-induced 
apoptosis, we overexpressed variant 1 of OPA1 lacking 
the S1 cleavage site (OPA1-ΔS1), a non-cleavable 
long form of OPA1 [42]. Strikingly, fluorizoline could 
efficiently induce apoptosis in the presence of OPA1-ΔS1 
(Supplementary Figure 4a-b), suggesting that the loss 
of L-OPA1 is not required for the pro-apoptotic effects 
of fluorizoline. To confirm these results, we used MEFs 
lacking OMA1, a mitochondrial protease that cleaves 
OPA1 in response to several stress insults [43-47]. 
Fluorizoline treatment triggered the loss of L-OPA1 in WT 
MEFs, while Oma1-/- MEFs maintained L-OPA1 forms 
even in the presence of fluorizoline. In contrast, WT and 
Oma1-/- MEFs showed a similar response to fluorizoline 
(Supplementary Figure 4c-d). All together, these results 
prove that fluorizoline does not rely on stress-induced loss 
of L-OPA1 forms to induce apoptosis. 
Fluorizoline increases the production of reactive 
oxygen species independently of PHBs and 
apoptosis induction
We analyzed the effects of fluorizoline on the 
mitochondrial membrane potential (ΔΨm) as an indicator 
of mitochondrial function. As apoptosis induction can 
affect ΔΨm [39], it was important to analyze ΔΨm before 
the onset of cell death. To this end, we used Jurkat cells, as 
previous results from our group showed that cytochrome 
c was released from mitochondria after 8 h of fluorizoline 
treatment [2]. Interestingly, 8 h of fluorizoline treatment 
resulted only in a slight loss of ΔΨm (Supplementary 
Figure 5), which suggests that it is a consequence of 
apoptosis induction.
In addition, we sought to analyze whether treatment 
with fluorizoline leads to generation of reactive oxygen 
species (ROS) by using CellROX® Deep Red reagent, 
which detects superoxide anion and hydroxyl radical. 
Jurkat cells showed increased ROS production upon 
treatment with fluorizoline for 1 h (Figure 3a). In order 
to study the involvement of ROS in fluorizoline-induced 
apoptosis, we pre-treated cells with the SOD mimetic 
manganese (III)-tetrakis (4-benzoic acid) porphyrin 
(MnTBAP), which efficiently inhibited fluorizoline-
induced ROS production (Figure 1d), while it could 
not revert the apoptotic effects of fluorizoline (Figure 
3c). Furthermore, we analyzed the production of ROS 
in Phb2-downregulated MEFs, which were resistant to 
fluorizoline-induced apoptosis (Figure 1a). Importantly, 
the absence of PHBs could not inhibit the generation of 
ROS induced by fluorizoline (Figure 3d). All together, 
these results demonstrate that fluorizoline does not require 
the generation of ROS to induce apoptosis.
Fluorizoline induces the mitochondrial apoptotic 
pathway in a BAX/BAK-dependent manner
The execution of apoptosis depends on the balance 
between pro- and anti-apoptotic BCL-2 family members 
[48, 49]. BAX and BAK are two multidomain pro-
apoptotic proteins whose activation leads to mitochondrial 
Figure 4: Fluorizoline-induced apoptosis occurs 
through the mitochondrial pathway in a BAX- and 
BAK-dependent manner. a. WT, Bax-/-, Bak-/- or Bax-/-/
Bak-/- MEFs were untreated (UT) or treated with 10 or 20 μM 
fluorizoline for 24 h. b., c. HeLa cells were transfected with 
scramble (SC) or BAX and BAK siRNA (siBAX/BAK) for 48 h. b. 
The efficiency of gene silencing was validated by western blot. 
β-Actin was used as a loading control. This is a representative 
image of at least three independent experiments. c. HeLa cells 
were untreated (UT) or treated with 5 or 10 μM fluorizoline (F) 
for 24 h. a., c. Viability was measured by flow cytometry and 
it is expressed as the mean ± SEM (n≥3) of the percentage of 
non-apoptotic cells (annexin V-negative).*p < 0.05, **p < 0.01.
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outer membrane permeabilization (MOMP) and the 
release of mitochondrial intermembrane proteins such 
as cytochrome c, two critical steps in the execution of 
apoptosis [48, 49]. In order to evaluate the role of BAX 
and BAK in fluorizoline-induced apoptosis, we used 
Bax-/-, Bak-/- and Bax-/-/Bak-/- MEFs, which are resistant 
to multiple cell death stimuli that induce apoptosis 
through MOMP [50]. Importantly, fluorizoline triggered 
apoptosis in WT MEFs, while the absence of both BAX 
and BAK significantly prevented the cytotoxic effects of 
this compound (Figure 4a). Bax-/- MEFs were as sensitive 
to fluorizoline as WT MEFs, although Bak-/- MEFs 
offered some resistance to the apoptosis induced by this 
compound. 
To corroborate these results, HeLa cells were 
transiently depleted of these two pro-apoptotic proteins 
by siRNA transfection (Figure 4b). Consistently, depletion 
of BAX and BAK reduced the apoptotic response to 
fluorizoline treatment (Figure 4c). 
To confirm the importance of the activation of 
the intrinsic apoptotic pathway, we used Jurkat cells 
overexpressing BCL-XL [51]. This is an anti-apoptotic 
member of the BCL-2 family, whose overexpression 
can block the intrinsic pathway of apoptosis [51, 52]. 
Fluorizoline was able to induce apoptosis in WT Jurkat 
cells, while overexpression of BCL-XL conferred 
resistance to the pro-apoptotic effects of fluorizoline 
(Supplementary Figure 6a-b).
Although the lack of BAX and BAK conferred 
significant resistance to fluorizoline treatment, cell 
Figure 5: Fluorizoline modulates the expression of BCL-2 family members by targeting PHBs in MEFs. a. Phb2fl/fl MEFs 
were untreated (white bars) or treated with 20 µM fluorizoline (black bars) for 24 h. b. Phb2fl/fl MEFs were transduced with Cre recombinase 
for 72 h (Phb2-/-) and then untreated or treated with 20 µM fluorizoline for 24 h. a., b. mRNA levels were analyzed by RT-MLPA. White 
bars correspond to untreated cells, and black bars to fluorizoline-treated cells. Data show the mean values ± SEM of three independent 
experiments relative to the mean of the control. *p < 0.05, **p < 0.01, ***p < 0.001 untreated versus treated cells.
Oncotarget41756www.impactjournals.com/oncotarget
viability was still slightly decreased. Pre-treatment of 
Bax-/-/Bak-/- MEFs with the pan-caspase inhibitor Q-VD-
OPh completely blocked fluorizoline-induced apoptosis 
(Supplementary Figure 6c). As the intrinsic apoptotic 
pathway is blocked in the absence of BAX and BAK, we 
assessed the role of the extrinsic apoptotic pathway by 
adding the caspase 8 inhibitor Z-IETD-FMK. Strikingly, 
inhibiting caspase 8 activity did not have any effect on 
fluorizoline-induced apoptosis in WT MEFs, while it 
could efficiently prevent the pro-apoptotic effects of 
fluorizoline in Bax-/-/Bak-/- MEFs (Supplementary Figure 
6c). To corroborate these results, we used Bax-/-/Bak-/- 
MEFs overexpressing CrmA, a cowpox virus protein that 
preferentially inhibits caspase 8 [53]. Consistently, CrmA 
effectively inhibited apoptosis induced by fluorizoline 
in Bax-/-/Bak-/- MEFs (Supplementary Figure 6d). All 
together, these findings show that the mitochondrial 
apoptotic pathway is essential for fluorizoline-induced 
apoptosis. Strikingly, in the absence of BAX and BAK, 
fluorizoline induces a minor decrease in viability by 
activating caspase 8.
Prohibitins mediate the modulation of the 
expression of various BCL-2 family members 
upon fluorizoline treatment
To gain insight into the mechanism of apoptosis 
induction upon fluorizoline treatment, changes in the 
overall apoptosis mRNA expression profile were analyzed 
by reverse transcriptase multiplex ligation-dependent 
probe amplification (RT-MLPA) in Phb2fl/fl MEFs. After 24 
h of treatment with 20 μM fluorizoline, the upregulation of 
the pro-apoptotic genes Bim, Noxa, Bmf, and Moap1 was 
observed, along with downregulation of the anti-apoptotic 
genes Bcl-2 and Bcl-X (Figure 5a and Supplementary 
Figure 7a). 
Fluorizoline-induced apoptosis requires the presence 
of PHBs (Figure 1). It is therefore conceivable that the 
modulations observed in apoptosis-related gene expression 
do not occur in cells lacking PHBs. To test this hypothesis, 
we transduced Phb2fl/fl MEFs with Cre-recombinase for 
72 h and then treated them with 20 μM fluorizoline for 
24 h. Importantly, Cre-mediated loss of PHBs abolished 
Figure 6: Fluorizoline changes mRNA and protein levels of various BCL-2 family members in HeLa cells. a. HeLa cells 
were untreated (white bars) or treated with 10 µM fluorizoline (black bars) for 24 h. mRNA levels were analyzed by RT-MLPA. Data show 
the mean values ± SEM of three independent experiments relative to the mean of the control. *p < 0.05, **p < 0.01, ***p < 0.001 untreated 
versus treated cells. b. HeLa cells were untreated or treated with 10 µM fluorizoline for 4, 8 and 24 h. c. HeLa cells were pre-incubated with 
20 µM caspase inhibitor Q-VD-OPh for 30 min and then treated with 10 µM fluorizoline for 24 h. b., c. Protein levels were analyzed by 
western blot. Tubulin was used as a loading control. These are representative images of at least three independent experiments. 
Oncotarget41757www.impactjournals.com/oncotarget
the modulations of mRNA levels triggered by fluorizoline 
(Figure 5b and Supplementary Figure 7b). Thus, the 
presence of PHBs is required for fluorizoline-induced 
changes in the apoptosis-related mRNA expression profile.
Interestingly, treatment with fluorizoline increased 
BIM protein levels in Phb2fl/fl MEFs, although these levels 
were not modulated in Phb2-/- MEFs (Supplementary 
Figure 8). NOXA protein levels could not be analyzed due 
to lack of proper antibodies with the capacity to detect the 
mouse protein (data not shown). Consequently, we further 
studied fluorizoline-induced apoptosis by analyzing 
changes in the expression of BCL-2 family members in 
HeLa cells, as there are more antibodies available for the 
detection of human BCL-2 family proteins. 
First, the apoptosis-related gene expression profile 
was examined by RT-MLPA in HeLa cells. Treatment 
with 10 μM fluorizoline increased the pro-apoptotic BIM, 
PUMA, NOXA, and BAK mRNA levels (Figure 6a and 
Supplementary Figure 9). Next, we sought to examine 
whether these modulations of the mRNA levels resulted 
in changes in the corresponding protein levels. We 
observed a time-dependent upregulation of NOXA and 
BIM, as well as decreases in PUMA and MCL-1 protein 
levels (Figure 6b). Despite the decreases in BCL-2 mRNA 
levels, fluorizoline did not significantly modulate its 
protein levels, a finding consistent with the long half-life 
of this protein [54]. In addition, PHB protein levels were 
not modified upon fluorizoline treatment. Interestingly, 
increases in NOXA and BIM preceded caspase activation, 
as pre-incubation with pan-caspase inhibitor Q-VD-OPh 
did not block their upregulation (Figure 6c). In contrast, 
caspase inhibition abolished the decrease in MCL-1 
mediated by fluorizoline treatment, thereby demonstrating 
that it is a caspase-dependent event. Thus, PHBs mediate 
fluorizoline-induced changes in Noxa and Bim expression, 
the protein levels of which increased prior to caspase 
activation. These modulations could explain the apoptotic 
outcome observed.
To validate the increases in BIM and NOXA protein 
levels, we analyzed the effects of fluorizoline in primary 
cancer cells. Specifically, we used cells from four patients 
with different hematological malignancies, namely 
chronic myeloid leukemia-derived blast crisis, mantle cell 
lymphoma, B cell chronic lymphoproliferative syndrome 
and adult T-cell leukemia/lymphoma. Interestingly, 
treatment with fluorizoline resulted in a decrease in 
viability and an increase in NOXA protein levels, whereas 
BIM protein levels were not modified (Supplementary 
Figure 10a-d). We also analyzed changes in BCL-2 family 
members following fluorizoline treatment in various 
cancer cell lines. NOXA and BIM protein levels increased 
in a dose-dependent manner in HT-29, a colon cancer cell 
line, as well as in A375P and WM1552, two melanoma 
cell lines (Supplementary Figure 10e-f). In Jurkat cells, 
we only observed fluorizoline-induced increases in 
NOXA protein levels (Supplementary Figure 10g). Hence, 
fluorizoline seems to mainly increase NOXA protein 
levels, while BIM is also upregulated in some cancer cells.
Role of NOXA and BIM in fluorizoline-induced 
apoptosis
We sought to further study the role of NOXA 
and BIM in fluorizoline-induced apoptosis. To this end, 
we performed a viability assay in MEFs lacking Noxa, 
Figure 7: Loss of NOXA and BIM blocks 
fluorizoline-induced apoptosis. a. WT, Noxa-/-, Bim-/- or 
Noxa-/-/Bim-/- MEFs were untreated (UT) or treated with 10, 15 or 
20 μM of fluorizoline for 24 h. b., c. HeLa cells were transfected 
with scramble (SC), NOXA siRNA (siNOXA), BIM siRNA 
(siBIM), or both NOXA and BIM siRNA (siNOXA/BIM) for 48 h 
and then untreated (UT) or treated with 5 or 10 μM fluorizoline 
(F) for 24 h. b. Protein levels were analyzed by western blot. 
Tubulin was used as a loading control. This is a representative 
image of at least three independent experiments. a., c. Viability 
was measured by flow cytometry and it is expressed as the mean 
± SEM (n ≥ 3) of the percentage of non-apoptotic cells (annexin 
V-negative).*p < 0.05, **p < 0.01, ***p < 0.001.
Oncotarget41758www.impactjournals.com/oncotarget
Bim, or both. Noxa-/-/Bim-/- MEFs were resistant to 
the pro-apoptotic effects of fluorizoline, whereas WT, 
Noxa-/- and Bim-/- MEFs showed a similar sensitivity to this 
compound (Figure 7a). In addition, NOXA and BIM were 
downregulated by siRNA transfection in HeLa cells and 
their response to fluorizoline treatment was assessed. Cells 
lacking BIM were sensitive to the pro-apoptotic effects 
of fluorizoline, while lack of NOXA conferred resistance 
to these effects. Simultaneous depletion of NOXA and 
BIM did not increase resistance to this compound when 
compared to depletion of NOXA alone (Figure 7b-7c).
All together, these data demonstrate that 
fluorizoline induces the mitochondrial apoptotic pathway 
predominantly through the upregulation of NOXA and, 
depending on the cell type, also of BIM.
DISCUSSION
In the present study we describe the mechanism of 
apoptosis induction exerted by fluorizoline, a new pro-
apoptotic agent with a fluorinated thiazoline scaffold. It 
was previously described that fluorizoline directly binds 
to PHB1 and PHB2 [2]. Here we show that PHBs mediate 
the pro-apoptotic effects of fluorizoline through two 
approaches. Depletion of Phb2 either by Cre-mediated 
recombination in Phb2fl/fl MEFs or by siRNA transfection 
in MEFs conferred resistance to fluorizoline. Hence, 
fluorizoline is a new synthetic agent that reduces cell 
viability by specifically targeting PHBs.
PHBs play a key role in the maintenance of 
mitochondrial homeostasis. High expression of PHBs has 
been found in cells that heavily depend on mitochondrial 
function, notably proliferating cells. It is conceivable 
that these cells are particularly susceptible to the lack of 
functional PHBs [4]. In fact, downregulation of PHBs in 
various cell lines blocks cell proliferation [10, 22, 35] 
and also induces apoptosis [13, 55, 56]. Overexpression 
of PHBs protects cells from apoptosis induced by various 
stimuli, an observation that is consistent with PHB1 
having a cytoprotective role [11]. In MEFs, PHBs exert 
their anti-apoptotic function via L-OPA1, as the increased 
sensitivity to apoptosis observed in the absence of PHBs 
can be counteracted by re-expression of a non-cleavable 
variant of L-OPA1 [10]. In addition, it has been reported 
that PHB overexpression inhibits apoptosis through 
the induction of BCL-2 and BCL-XL [23] and that 
downregulation of PHBs reduces BCL-XL levels [57]. 
Interestingly, overexpression of BCL-XL protected cells 
from fluorizoline-induced apoptosis.
The role of PHBs in cancer has been largely 
discussed. Although some reports point to an anti-
tumorigenic role of PHBs, a growing body of evidence 
links these proteins to tumor development [11, 21, 29, 
34, 35]. Fluorizoline has the capacity to induce apoptosis 
in a wide range of cancer cell lines, including glioma 
and prostate cancer cell lines [2], in which PHBs were 
reported to have an anti-tumorigenic role [31, 32]. Thus, 
the induction of apoptosis by targeting PHBs emerges as a 
new therapy for cancer.
The exact mechanism by which fluorizoline induces 
apoptosis remains to be elucidated. The loss of either 
PHB1 or PHB2 may destabilize mitochondrial PHBs 
complexes, leading to the activation of quality control 
mechanisms, which would in turn degrade the other 
partner [6, 58]. Therefore, the observation that PHB 
protein levels are maintained upon fluorizoline treatment 
suggests that the PHBs ring-like complex in the IMM is 
not destabilized. Treatment with fluorizoline increased the 
production of ROS, as observed in the absence of PHBs in 
various cell types [16-19, 24, 59, 60]. However, we proved 
that the generation of ROS was independent of PHBs 
and apoptosis induction, discarding oxidative stress as a 
mechanism of action of fluorizoline. PHBs are known to 
physically interact with several subunits of complex I and 
II of the respiratory chain, presumably contributing to their 
proper assembly and stability [61-63]. In fact, deletion of 
PHBs decreases the activity of various complexes of the 
respiratory chain [16, 26, 59]. We cannot exclude that 
fluorizoline will affect the activity of these complexes due 
to its PHBs-binding properties.
Treatment with fluorizoline induces fragmentation 
of the mitochondrial network, cristae remodeling and 
loss of L-OPA1, which is consistent with the role of this 
protein in mitochondrial fusion and in the maintenance 
of cristae structure [14, 15]. Strikingly, PHB-depleted 
cells also present fragmented mitochondrial network and 
aberrant cristae morphogenesis, which are attributed to 
the loss of L-OPA1 [10]. However, it is worth mentioning 
that this observation cannot be exclusively interpreted as 
a proof that fluorizoline targets PHBs. Other apoptotic 
stimuli have been reported to trigger the same changes 
in mitochondrial structure [38-41] and the processing 
of L-OPA1 [42, 64, 65], which allows reorganization of 
mitochondrial cristae and facilitates cytochrome c release 
[66, 67]. Our results demonstrate that fluorizoline was able 
to induce apoptosis independently of the loss of L-OPA1 
forms, which excludes this event as the cause of apoptosis 
induction.
We have shown that fluorizoline triggers the intrinsic 
apoptotic pathway, as BAX and BAK are required for 
fluorizoline-induced apoptosis. The protection observed 
in Bak-/- MEFs could be related to the recently reported 
requirement of BAK for efficient BAX translocation and 
oligomerization at the outer mitochondrial membrane [68]. 
The activation of the intrinsic apoptotic pathway involving 
BCL-2 family members appears to be necessary for the 
successful outcome of many cancer treatments [48]. 
Expression analysis revealed a consistent upregulation of 
two BH3-only proteins, namely the activator Bim and the 
sensitizer Noxa in MEF and HeLa cells upon fluorizoline 
treatment. Of note, these modulations were dependent on 
the presence of PHBs in MEFs.
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Importantly, fluorizoline induced increases in 
NOXA and BIM protein levels prior to caspase activation, 
which could explain the apoptotic outcome. NOXA 
and BIM are essential for the induction of apoptosis in 
response to a variety of pro-apoptotic insults [48, 69-71]. 
The lack of NOXA in HeLa cells conferred resistance 
to the pro-apoptotic effects of fluorizoline, although this 
was not observed in Noxa-/- MEFs. These observations are 
consistent with the reported differences in the apoptotic 
potential of NOXA in function of the cell type [70]. 
Specifically, NOXA overexpression induces significant 
apoptosis in HeLa cells [72], while in MEFs it is poorly 
apoptotic [73, 74]. In MEFs, lack of NOXA and BIM 
conferred significant resistance to fluorizoline-induced 
apoptosis, thus revealing a key role for these BH3-only 
proteins in the mechanism of action of fluorizoline. On 
the other hand, downregulation of both NOXA and BIM in 
HeLa cells failed to offer more protection than the absence 
of NOXA alone, thereby suggesting that BIM plays only 
a minor role in these cells. The consistent upregulation 
of NOXA protein levels in all the cancer cell types that 
were analyzed points towards a main function of this BH3-
only protein in fluorizoline-induced apoptosis. Compared 
to PHB-depleted cells, the loss of the crucial BH3-only 
proteins (i.e. NOXA and BIM for MEFs and NOXA for 
HeLa cells) blocked fluorizoline-induced apoptosis less 
efficiently, thus suggesting a contribution of other BCL-2 
family members modulated in a PHB-dependent manner. 
In addition to their role in mitochondria, PHBs also 
localize in other cellular compartments, including the 
nucleus and the plasma membrane, in a wide range of 
cell types [11, 75]. In the plasma membrane, PHBs have 
been involved in the activation of the signaling pathways 
Ras-Raf-MAPK and the tyrosine kinase Syk [76-79]. In 
the nucleus, PHBs were reported to regulate the activity 
of various transcription factors such as p53, E2F1, and 
estrogen receptor [11]. Whether the fluorizoline-induced 
transcriptional modulations are directly mediated by 
nuclear PHBs or indirectly mediated by PHBs in other 
cellular compartments requires further analysis.
Similar to fluorizoline, the effects of three natural 
products that bind to PHBs have been reported. First, 
capsaicin binds to PHB2 to induce cytochrome c release 
from mitochondria [80]. Second, the depsipeptide 
aurilide was shown to selectively bind to PHB1 in 
the mitochondria, leading to rapid mitochondrial 
fragmentation and the induction of apoptosis [81]. Third, 
Rocaglamide A, a member of the flavagline class of 
compounds, binds to both PHB1 and PHB2 at the cell 
membrane to inhibit Raf activation and Raf-MEK-ERK-
mediated cell cycle progression and cell proliferation 
in tumor cell lines, without inducing mitochondrial 
fragmentation [82]. Interestingly, Rocaglamide A and 
other related flavaglines have pro-apoptotic activities 
both in vitro and in vivo in various cancer cells; however, 
it remains unknown whether PHBs are involved in 
their mechanism of apoptosis induction [11, 83]. The 
complexity of the synthesis or the restricted availability of 
these compounds may hinder their use in therapeutics. In 
contrast, fluorizoline synthesis is practical, versatile, short, 
and reproducible, and thus amenable to gram-scale batches 
[2]. In vivo, sub-acute toxicity studies in mice revealed 
that fluorizoline only produces some liver toxicity at the 
higher doses that were tested (data not shown). Thus, it 
would be possible to analyze its anti-tumor effects in vivo.
In conclusion, this study demonstrates that PHBs are 
required for fluorizoline-induced apoptosis. PHBs mediate 
the upregulation of NOXA and BIM, which are crucial 
for the pro-apoptotic effects of fluorizoline. Moreover, 
our findings reveal that PHBs are amenable to modulation 
by small molecules to finally induce apoptosis, and thus 
further contributes to highlighting the suitability of PHBs 
as promising therapeutic targets. 
MATERIALS AND METHODS
Reagents
The synthesis of racemic fluorizoline was performed 
as previously described [2]. Actinomycin D was purchased 
from Enzo Life Sciences (Farmingdale, New York, USA). 
Q-VD-OPh and Z-IETD-FMK were from R&D systems 
(Minneapolis, Minnesota, USA). Recombinant mouse 
TNFα was from PeproTech (Rocky Hill, New Jersey, 
USA). MnTBAP, etoposide and cycloheximide were from 
Sigma-Aldrich (Saint Louis, Missouri, USA). 
Cell lines culture
WT and Phb2fl/fl MEFs were generated as 
previously described [10]. Phb2fl/- MEFs were generated 
by transducing Phb2fl/fl MEFs with Cre recombinase for 
72 h. Cells were sorted individually in a 96-well plate 
and then allowed to grow for several days. Genotyping 
was performed by PCR analysis as previously described 
[10]. MEFs WT, Bax-/-, Bak-/- and Bax-/-/Bak-/- MEFs were 
obtained from Dr. Korsmeyer’s laboratory [50]. HeLa and 
Jurkat cells were supplied by the European Collection of 
Cell Culture. Oma1-/- MEFs were a kind gift of Dr. Lopez-
Otín (Instituto Universitario de Oncología, Universidad de 
Oviedo, Spain). WT, Bim-/-, Noxa-/- and Bim-/-/Noxa-/- MEFs 
were kindly provided by Dr. Andreas Villunger (Medical 
University of Innsbruck, Austria). Jurkat-BCL-XL cells 
were generated by Dr. Victor Yuste (Universitat Autònoma 
de Barcelona, Spain). Bax-/-/Bak-/- MEFs overexpressing 
CrmA were kindly provided by Dr. Muñoz-Pinedo [84]. 
HT29 and MW1552 cells were supplied by ATCC. A375P 
cells were provided by Dr. I. J. Fidler (MD Anderson 
Cancer Center, Houston, USA).
All cell lines were cultured in Dulbecco’s Modified 
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Eagle Medium except for Jurkat, which were cultured 
in Roswell Park Memorial Institute (RPMI) 1640 
Medium supplemented with 10% fetal bovine serum, 2 
mM L-glutamine, 100 U/mL penicillin, and 100 ng/mL 
streptomycin (all from Biological Industries, Israel) at 
37°C in a humidified atmosphere containing 5% carbon 
dioxide.
Primary samples and cell isolation
Peripheral blood samples and bone marrow aspirates 
from untreated patients were obtained after informed 
consent in accordance with protocols approved by the 
Human Research Ethics Committees of the Hospital 
ICO-Duran i Reynals, L’Hospitalet de Llobregat, 
Spain. Patients with chronic myeloid leukemia-derived 
blast crisis, mantle cell lymphoma, B cell chronic 
lymphoproliferative syndrome and adult T-cell leukemia/
lymphoma were diagnosed according to standard clinical 
and laboratory criteria. Peripheral blood and bone marrow 
mononuclear cells were isolated by centrifugation on a 
Biocoll (Biochrom AG, Berlin, Germany) gradient and 
cryopreserved in liquid nitrogen in the presence of 10% 
DMSO (Sigma-Aldrich). Mononuclear cells were cultured 
immediately after thawing or isolation at a concentration 
of 1x106 cells/mL in RPMI 1640 culture medium 
supplemented with 10% heat-inactivated fetal bovine 
serum, 2 mM L-glutamine, 100 U/mL penicillin, and 100 
µg/mL streptomycin (all from Biological Industries) at 
37 ºC in a humidified atmosphere containing 5% carbon 
dioxide.
Transduction of MEFs with Cre-recombinase
Recombinant His-TAT-NLS-Cre-recombinase 
(HTNC) was expressed and purified as previously 
described [85]. 6 μM HTNC was diluted in DMEM/PBS 
(1:1), sterile filtered and applied to WT and Phb2fl/fl MEFs 
for 20 h. Afterwards, cells were washed with PBS and 
grown in complete medium for 48 h. MEFs were then 
treated with fluorizoline for 24 h.
Analysis of cell viability by flow cytometry
Cell viability was measured by exposure of 
phosphatidylserine and expressed as the percentage of 
annexin V-APC-negative population. Cells were washed 
and incubated with annexin binding buffer and annexin 
V-APC for 15 min in the dark and then analyzed by flow 
cytometry using FACSCalibur and CellQuest-Pro software 
(BD Biosciences, Franklin Lakes, New Jersey, USA).
Western blot
Whole cell protein extracts were obtained by 
lysing cells with Laemmli sample buffer or RIPA buffer 
(Supplementary Figure 1b). Protein concentration was 
measured with the Micro BCA Protein Assay Reagent 
kit (Pierce, Rockford, Illinois, USA). 20-50 µg of 
protein extracts were subjected to reducing conditions, 
loaded onto a polyacrylamide gel and then transferred 
to Immobilon-P membranes from Millipore (Billerica, 
Massachusetts, USA) or Protran 0.2 nitrocellulose 
membranes from Amersham (Buckinghamshire, UK) 
(Supplementary Figure 1b). One hour after blocking 
with 5% (w/v) non-fat milk in Tris-buffered saline with 
Tween® 20, membranes were incubated with the following 
specific primary antibodies: cleaved caspase 3 (9661, Cell 
Signalling, Danvers, Massachusetts, USA); PARP (9542, 
Cell Signalling); OPA1 (612607, BD Biosciences); PHB1 
(H-80, Santa Cruz, Dallas, Texas, USA); PHB2 (07-234, 
Millipore); Tubulin (CP06, Millipore); β-Actin (A5441, 
Sigma-Aldrich); ERK2 (clone 1B3B9, 05-157, Millipore); 
BAX (AB2915, Millipore); BAK (06-536, Millipore); 
BCL-XL (B22630, Transduction Laboratories); MCL-1 
(S-19, sc-819, Santa Cruz); BIM (2933, Cell Signaling); 
NOXA (ab13654, Abcam, Cambridge, UK); PUMA 
(4976, Cell Signaling); and BCL-2 (M0887, Dako, Santa 
Clara, California, USA). For Supplementary Figure 
1b, we used different antibodies for PHB1 (603102, 
BioLegend, San Diego, California) and PHB2 (611802, 
BioLegend). Antibody binding was detected using a 
secondary antibody conjugated to horseradish peroxidase, 
and the enhanced chemiluminescence detection system 
(Amersham). Molecular size markers (#26619, Thermo 
Fisher Scientific) are indicated in kDa in each figure.
Transient transfection
siRNA transfection. MEFs were transfected with 
scramble (12935-300) or Phb2 siRNA (MSS236022), 
while HeLa cells were transfected with scramble (12935-
300), BAK (HSS141354, HSS141355, HSS141356), 
BAX (HSS184085, HSS184086, HSS184087), NOXA 
(HSS143341, HSS143342, HSS143343), or BIM 
(s195011) siRNA using the Lipofectamine® RNAiMax 
Reagent (all from Thermo Fisher Scientific, Waltham, 
Massachussets, USA). Complexes were added directly 
to growing cells in DMEM and incubated for 24 h, 
followed by washing with PBS buffer and addition of 
fresh DMEM. MEFs were used in experiments 72 h after 
siRNA transfection, and HeLa cells were used after 48 
h. The efficiency of the downregulation was assessed 
by western blot. Plasmid transfection. HeLa cells were 
transfected with either pcDNA3.1, OPA1-ΔS1 construct 
(kindly provided by Dr. Ishihara, Kurume University, 
Japan) or 3X-FLAG PHB1 and PHB2 plasmids (a kind 
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gift of Dr. Handa, Tokyo Institute of Technology, Japan) 
using the Lipofectamine® LTX Reagent (Thermo Fisher 
Scientific). Cells were used in experiments 48 h after 
transfection. MEFs were transfected with PHB1 and 
PHB2 overexpression plasmids using the Lipofectamine® 
2000 Reagent (Thermo Fisher Scientific). Complexes 
were incubated for 25 min at room temperature and added 
dropwise to growing cells in DMEM. Cells were used in 
experiments 16 h after transfection. The efficiency of the 
overexpression was assessed by western blot.
Fluorescence imaging
HeLa cells were grown on sterilized poly-L-lysine-
coated coverslips (0.01% solution, Sigma-Aldrich) and 
incubated with 100 nM MitoTracker® Red CMXRos 
(Thermo Fisher Scientific) for 30 min at 37°C. Cells 
were visualized using spectral confocal microscope 
(TCS-SL, Leica Microsystems, Wetzlar, Germany) 
and a Plan-Apochromat 63×/1.4 N.A. immersion oil 
objective (Leica Microsystems). Images were acquired 
using the accompanying image processing software from 
Cytovision.
Transmission electron microscopy
HeLa cells were rinsed with PBS and immediately 
fixed by immersion in 0.1 M glutaraldehyde in phosphate 
buffer for 2-3 h at 4°C. Cells were gently scraped, 
collected, and pelleted by centrifugation. Cells were 
treated with 1% osmium tetroxide and after dehydration 
were embedded in epoxy resin (Araldite, Basel, 
Switzerland). Thin sections were cut with a diamond knife 
on a ultramicrotome (Ultracut, Reichert-Jung, Depew, 
New York, USA), stained with uranyl actetate/lead citrate 
and each sample was placed into grids to be examined in a 
JEOL 1010 electron microscope equipped with a Bioscan 
digital camera (Gatan, Pleasanton, California, USA). 
ROS production
Superoxide anion and hydroxyl radical production 
was analyzed by incubating Jurkat or MEF cells with 
2.5 μM CellROX® Deep Red Reagent (Thermo Fisher 
Scientific) during the last 30 min of the treatment at 
37°C. ROS production was measured by flow cytometry 
using FACSCalibur and CellQuest-Pro software (BD 
Biosciences), and expressed as the mean fluorescence 
intensity relative to the mean of the control. 
Measurement of mitochondrial membrane 
potential
Jurkat cells were stained with 100 nM MitoTracker® 
Red CMXRos (Thermo Fisher Scientific) during the last 
30 min of the treatment at 37ºC and then analyzed by flow 
cytometry using MoFlo® Astrios (Beckman Coulter, Brea, 
California, USA). Decreased fluorescence indicates a loss 
of ∆Ψm.
Reverse transcriptase multiplex ligation-
dependent probe amplification (RT-MLPA)
RNA content was analyzed by RT-MLPA using the 
SALSA MLPA KIT RM002-B1 (MEFs) and R011-C1 
(HeLa cells) Apoptosis mRNA from MRC-Holland 
(Amsterdam, The Netherlands) for the simultaneous 
detection of 40 mRNA molecules [86]. In brief, 200 ng 
total RNA were first reverse transcribed using a gene 
specific primer mix. The resulting cDNA was annealed 
overnight at 60°C to the RT-MLPA probe mix. Annealed 
oligonucleotides were ligated by adding Ligase-65 (MRC-
Holland) and incubated at 54°C for 15 min. Ligation 
products were amplified by PCR (35 cycles, 30 s at 95°C; 
30 s at 60°C, and 1 min at 72°C) with one unlabeled 
and one FAM-labeled primer. PCR fragments were 
separated by capillary electrophoresis on a 48-capillary 
ABI-Prism 3730 Genetic Analyzer (Applied Biosystems, 
California, USA). Peak area and height were measured 
using GeneMapper v3.0 analysis software (Applied 
Biosystems). Individual peaks were calculated relative to 
the sum of all peak data to normalize for fluctuations in 
total signals between samples. Data are shown as the mean 
± SEM relative to the mean of the controls.
Statistical analysis
The results are shown as the mean ± standard 
error of the mean (SEM) of values obtained in three or 
more independent experiments. Statistical analysis was 
performed using the Student’s t test (two-tailed) by using 
GraphPad Prism 6.0c Software Inc. p values below 0.05 
were considered statistically significant (*p < 0.05; **p < 
0.01; ***p < 0.001).
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